European Childhood Obesity Project: Early Programming by Infant Nutrition?
Launched by LUDWIG-MAXIMILIANS - UNIVERSITY OF MUNICH · Jun 19, 2006
Trial Information
Current as of July 21, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The European Childhood Obesity Project is a research study focused on understanding how the type of nutrition infants receive can affect their growth and risk of becoming overweight as children. The main idea is that the amount of protein in infant formula might influence how much weight babies gain and, ultimately, their chances of being obese later in life. Researchers will compare different types of infant formulas with varying protein levels to see if this makes a difference in childhood obesity rates. They will follow the babies in the study until they turn 18, looking at their body composition, hormones, and growth patterns.
To participate in this study, mothers must be at least 18 years old and have had a healthy pregnancy with a baby born after 37 weeks. The baby should be a single birth (not twins or more) and weigh enough for their age. However, mothers with certain health conditions, such as diabetes or drug addiction, or babies with serious health issues may not be able to join. Families in this study can expect to be part of a larger effort to improve dietary advice for parents and create better nutrition products for infants, all aimed at preventing childhood obesity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Gestational age \> 37 weeks
- • Appropriate for gestational age (above 10th percentile,Lubchenko)
- • Age of the mother at least 18 years
- • Singleton pregnancies
- • Residence in the study area
- • Maternal command of the language
- Exclusion Criteria:
- • Gestational diabetes
- • Major malformations (of the child) which might interfere with nutrition or growth
- • Hormonal or metabolic diseases of the mother or the child, drug addiction during pregnancy
About Ludwig Maximilians University Of Munich
Ludwig-Maximilians-University of Munich (LMU Munich) is a prestigious research institution in Germany, renowned for its commitment to advancing medical science and improving patient care through innovative clinical research. As a leading sponsor of clinical trials, LMU Munich leverages its extensive academic resources and interdisciplinary expertise to conduct rigorous studies aimed at evaluating new therapeutic interventions and advancing healthcare knowledge. The university fosters collaboration among researchers, clinicians, and healthcare professionals, ensuring that trials are designed and executed with the highest ethical standards and scientific integrity. Through its dedication to excellence in research, LMU Munich aims to contribute significantly to the development of effective treatments and enhance the overall health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Liège, , Belgium
Muenchen, , Germany
Milan, , Italy
Warsaw, , Poland
Tarragona, , Spain
Patients applied
Trial Officials
Berthold Koletzko, Prof.
Principal Investigator
Ludwig-Maximilians-Universitaet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials